Unleashing the Potential of Anti-CD45RB Antibodies in Transplantation.

BACKGROUND

Organ transplantation faces challenges of chronic rejection and infection due to immunosuppression. Inducing long-term immune tolerance is a key goal, with anti-CD45RB antibody being a studied target for decades.

METHODS

This review examines its mechanisms-modulating T cells (e.g.promoting Tregs), B cells, and cytokines-and efficacy across transplantation models (e.g.pancreatic, cardiac, cutaneous), including combination therapies.

CONCLUSIONS

Efficacy varies by model: monotherapy induced tolerance in certain islet transplants but not skin grafts. Combination with agents like anti-CD40L or rapamycin significantly prolonged graft survival (e.g.to 100% in heart transplants). Dosage, timing, and recipient immune status influence outcomes, with Treg involvement as a common mechanism.

FUTURE DIRECTIONS: Further research should explore synergies with clinical immunosuppressants and mechanisms in large animal xenografts to advance clinical translation.